NGM Biopharmaceuticals announces presentation on NGM936 at ASH

NGM Biopharmaceuticals "provided additional detail today on the poster presentation given on the Company’s first disclosed preclinical bispecific program, NGM936, at the American Society of Hematology Annual Meeting, which is taking place December 10 – 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. NGM936 was selected for further evaluation by NGM Bio from a panel of internally-developed ILT3 x CD3 engagers in various formats based on its ability in preclinical in vivo and in vitro studies to potently induce TDCC against ILT3+ AML cells while inducing minimal cytokine release. In those studies, NGM936 induced potent cytotoxicity comparable to a CD123 x CD3 biosimilar when both expanded and naive T cells were used as effectors. Importantly, NGM936 efficiently ablated tumor cells with a range of ILT3 expression, from ~1500 copies/cell to ~40,000 copies/cell, in those studies. In addition, as reported in the poster, NGM936 did not induce T cell-dependent cytotoxicity against CD34+ hematopoietic stem cells or non-monocytic immune cells, consistent with the lack of ILT3 expression on these cell types. In both whole blood cytokine releases assays and in TDCC assays in which cytokine secretion was measured after target engagement, induction of TNF-alpha, IL-6, IFN-gamma and IL-2 by NGM936 was considerably lower than that induced by a CD123 x CD3 biosimilar."